Researchers at City of Hope and TGen (part of City of Hope) have identified a significant correlation between a tumor’s “splicing burden” and its clinical response to treatment for metastatic renal cell carcinoma (mRCC). In a study published in the Journal for ImmunoTherapy of Cancer, researchers demonstrate that patients whose tumor tissue exhibits a high frequency of aberrant gene splicing are more likely to respond to therapy compared to those with fewer aberrant splicing events.
This article was originally published on MedicalXpress.com
